Source: Celgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing. A California whistleblower case, however, has moved forward with the unsealing of thousands of pages of new documents that attorneys for a former sales…...

Source: FierceBiotech The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering. The Durham, NC-based company, which is around a decade old, is working on nitric oxide based therapies for dermatologic indications, including acne. According to its SEC-1 filing, the…...